Biological markers in noninvasive brain stimulation trials in major depressive disorder: A systematic review

Journal of ECT

Volumn 30, Issue 1, 2014, Pages 47-61

  Fidalgo, Thiago M ^a,b   Morales Quezada, J Leon ^a,c   Muzy, Guilherme S C ^d   Chiavetta, Noelle M ^a   Mendonca, Mariana E ^a   Santana, Marcus V B ^a   Goncalves, Oscar F ^e   Brunoni, Andre R ^d   Fregni, Felipe ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

^d FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^e UNIVERSITY OF MINHO   (Portugal)

Author keywords

BDNF and EEG; biological markers; neuroimaging; transcranial magnetic stimulation

Indexed keywords

BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; ELECTRIC STIMULATION THERAPY; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGICAL PROCESSES; HUMANS; HYDROCORTISONE; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; NEUROSECRETORY SYSTEMS; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN; SPECTROSCOPY, NEAR-INFRARED; THYROID HORMONES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84894434209     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e31828b34d8     Document Type: Conference Paper

References (118)

1. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343-396.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
3. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17-25.
4. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49:124-138.
5. Brunoni AR, Teng CT, Correa C, et al. Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. Arq Neuropsiquiatr. 2010;68:433-451.
6. Pridmore S. Rapid transcranial magnetic stimulation and normalization of the dexamethasone suppression test. Psychiatry Clin Neurosci. 1999;53:33-37.
7. Zobel AW, Yassouridis A, Frieboes RM, et al. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry. 1999;156:949-951.
8. A decade for psychiatric disorders. Nature. 2010;463:9.
9. Akil H, Brenner S, Kandel E, et al. Medicine. The future of psychiatric research: genomes and neural circuits. Science. 2010;327:1580-1581.
10. Insel TR, Wang PS. Rethinking mental illness. JAMA. 2010;303:1970-1971.
11. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003;2:145-156.
12. LR, R. Magnetic stimulation of the central and peripheral nervous systems. In: Dumitru D, ed. Electrodiagnostic Medicine. Philadelphia, PA: Hadley & Belfus Inc; 1995:415-427.
13. Hahn T, Marquand AF, Ehlis AC, et al. Integrating neurobiological markers of depression. Arch Gen Psychiatry. 2011;68:361-368.
14. Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther. 2009;15:358-374.
15. Koyama R, Ikegaya Y. To BDNF or not to BDNF: that is the epileptic hippocampus. Neuroscientist. 2005;11:282-287.
16. Otte A, Halsband U. Brain imaging tools in neurosciences. J Physiol Paris. 2006;99:281-292.
17. Serkova NJ, Brown MS. Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. Bioanalysis. 2012;4:321-341.
18. Malhi GS, Lagopoulos J. Making sense of neuroimaging in psychiatry. Acta Psychiatr Scand. 2008;117:100-117.
19. Ziemann U. Transcranial magnetic stimulation at the interface with other techniques: a powerful tool for studying the human cortex. Neuroscientist. 2011;17:368-381.
20. Nahas Z, DeBrux C, Chandler V, et al. Lack of significant changes on magnetic resonance scans before and after 2 weeks of daily left prefrontal repetitive transcranial magnetic stimulation for depression. J ECT. 2000;16:380-390.
21. Li X, Nahas Z, Kozel FA, et al. Acute left prefrontal transcranial magnetic stimulation in depressed patients is associated with immediately increased activity in prefrontal cortical as well as subcortical regions. Biol Psychiatry. 2004;55:882-890.
22. Li X, Nahas Z, Lomarev M, et al. Prefrontal cortex transcranial magnetic stimulation does not change local diffusion: a magnetic resonance imaging study in patients with depression. Cogn Behav Neurol. 2003;16:128-135.
23. Herbsman T, Avery D, Ramsey D, et al. More lateral and anterior prefrontal coil location is associated with better repetitive transcranial magnetic stimulation antidepressant response. Biol Psychiatry. 2009;66:509-515.
24. Fitzgerald PB, Sritharan A, Daskalakis ZJ, et al. A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression. J Clin Psychopharmacol. 2007;27:488-492.
25. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193-207.
26. Kito S, Fujita K, Koga Y. Regional cerebral blood flow changes after low-frequency transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in treatment-resistant depression. Neuropsychobiology. 2008;58:29-36.
27. Kito S, Fujita K, Koga Y. Changes in regional cerebral blood flow after repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in treatment-resistant depression. J Neuropsychiatry Clin Neurosci. 2008;20:74-80.
28. Conca A, Peschina W, König P, et al. Effect of chronic repetitive transcranial magnetic stimulation on regional cerebral blood flow and regional cerebral glucose uptake in drug treatment-resistant depressives. A brief report. Neuropsychobiology. 2002;45:27-31.
29. Loo CK, Sachdev PS, Haindl W, et al. High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients. Psychol Med. 2003;33:997-1006.
30. Pogarell O, Koch W, Pöpperl G, et al. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study. J Psychiatr Res. 2006;40:307-314.
31. Nadeau SE, McCoy KJ, Crucian GP, et al. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15:159-175.
32. Peschina W, Conca A, König P, et al. Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study. Nucl Med Commun. 2001;22:867-873.
33. Baeken C, De Raedt R, Van Hove C, et al. HF-rTMS treatment in medication-resistant melancholic depression: results from 18FDG-PET brain imaging. CNS Spectr. 2009;14:439-448.
34. Herwig U, Lampe Y, Juengling FD, et al. Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. J Psychiatr Res. 2003;37:267-275.
35. McLean MA, Cross JJ. Magnetic resonance spectroscopy: principles and applications in neurosurgery. Br J Neurosurg. 2009;23:5-13.
36. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull. 2008;34:760-773.
37. Luborzewski A, Schubert F, Seifert F, et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res. 2007;41:606-615.
38. Eschweiler GW, Wegerer C, Schlotter W, et al. Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Res. 2000;99:161-172.
39. Boutros NN, Miano AP, Hoffman RE, et al. EEG monitoring in depressed patients undergoing repetitive transcranial magnetic stimulation. J Neuropsychiatry Clin Neurosci. 2001;13:197-205.
40. Olejniczak P. Neurophysiologic basis of EEG. J Clin Neurophysiol. 2006;23:186-189.
41. O'Sullivan SS, Mullins GM, Cassidy EM, et al. The role of the standard EEG in clinical psychiatry. Hum Psychopharmacol. 2006;21:265-271.
42. Cracco RQ, Amassian VE, Maccabee PJ, et al. Comparison of human transcallosal responses evoked by magnetic coil and electrical stimulation. Electroencephalogr Clin Neurophysiol. 1989;74:417-424.
43. Arns M, Spronk D, Fitzgerald PB. Potential differential effects of 9Hz rTMS and 10 Hz rTMS in the treatment of depression. Brain Stimul. 2010;3:124-126.
44. Price GW, Lee JW, Garvey C, et al. Appraisal of sessional EEG features as a correlate of clinical changes in an rTMS treatment of depression. Clin EEG Neurosci. 2008;39:131-138.
45. Narushima K, McCormick LM, Yamada T, et al. Subgenual cingulate theta activity predicts treatment response of repetitive transcranial magnetic stimulation in participants with vascular depression. J Neuropsychiatry Clin Neurosci. 2010;22:75-84.
46. Berman RM, Narasimhan M, Sanacora G, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry. 2000;47:332-337.
47. Schestatsky P, Morales-Quezada L, Fregni F. Simultaneous EEG monitoring during transcranial direct current stimulation (tDCS). J Vis Exp. 2012. In press.
48. Ziemann U, Corwell B, Cohen LG. Modulation of plasticity in human motor cortex after forearm ischemic nerve block. J Neurosci. 1998;18:1115-1123.
49. Bajwa S, Bermpohl F, Rigonatti SP, et al. Impaired interhemispheric interactions in patients with major depression. J Nerv Ment Dis. 2008;196:671-677.
50. Chistyakov AV, Kaplan B, Rubichek O, et al. Antidepressant effects of different schedules of repetitive transcranial magnetic stimulation vs. clomipramine in patients with major depression: relationship to changes in cortical excitability. Int J Neuropsychopharmacol. 2005;8:223-233.
51. Triggs WJ, McCoy KJ, Greer R, et al. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry. 1999;45:1440-1446.
52. Maeda F, Keenan JP, Pascual-Leone A. Interhemispheric asymmetry of motor cortical excitability in major depression as measured by transcranial magnetic stimulation. Br J Psychiatry. 2000;177:169-173.
53. Crevits L, Van den Abbeele D, Audenaert K, et al. Effect of repetitive transcranial magnetic stimulation on saccades in depression: a pilot study. Psychiatry Res. 2005;135:113-119.
54. Liang WK, Juan CH. Modulation of motor control in saccadic behaviors by TMS over the posterior parietal cortex. J Neurophysiol. 2012;108:741-752.
55. Reid PD, Pridmore S. Dexamethasone suppression test reversal in rapid transcranial magnetic stimulation-treated depression. Aust N Z J Psychiatry. 1999;33:274-277.
56. Zwanzger P, Baghai TC, Padberg F, et al. The combined dexamethasone-CRH test before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychoneuroendocrinology. 2003;28:376-385.
57. Gratacòs M, González JR, Mercader JM, et al. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry. 2007;61:911-922.
58. Yukimasa Fleck T, Yoshimura R, Tamagawa A, et al. Review of the guidelines of the Brazilian Medical Association for the treatment of depression (complete version). Rev Bras Psiquiatr. 2009;31 (suppl 1):S7-S17.
59. Ren K, Dubner R. Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: role of BDNF-TrkB signaling and NMDA receptors. Mol Neurobiol. 2007;35:224-235.
60. Yukimasa T, Yoshimura R, Tamagawa A, et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry. 2006;39:52-59.
61. Zanardini R, Gazzoli A, Ventriglia M, et al. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord. 2006;91:83-86.
62. Stipcevic̀ T, Pivac N, Kozaric̀ Kovacic̀ D et al. Thyroid activity in patients with major depression. Coll Antropol. 2008;32:973-976.
63. Kito S, Hasegawa T, Fujita K, et al. Changes in hypothalamic-pituitary- thyroid axis following successful treatment with low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression. Psychiatry Res. 2010;175:74-77.
64. Szuba MP, O'Reardon JP, Rai AS, et al. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression. Biol Psychiatry. 2001;50:22-27.
65. George MS, Wassermann EM, Williams WA, et al. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J Neuropsychiatry Clin Neurosci. 1996;8:172-180.
66. IsHak WW, Davis M, Jeffrey J, et al. The role of dopaminergic agents in improving quality of life in major depressive disorder. Curr Psychiatry Rep. 2009;11:503-508.
67. Miniussi C, Bonato C, Bignotti S, et al. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression? Clin Neurophysiol. 2005;116:1062-1071.
68. Kuroda Y, Motohashi N, Ito H, et al. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. J Affect Disord. 2006;95:35-42.
69. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407-430.
70. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(suppl 6):16-22.
71. Padberg F, di Michele F, Zwanzger P, et al. Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacology. 2002;27:874-878.
72. Huang CC, Wei IH, Chou YH, et al. Effect of age, gender, menopausal status, and ovarian hormonal level on rTMS in treatment-resistant depression. Psychoneuroendocrinology. 2008;33:821-831.
73. Esel E, Turan T, Kula M, et al. Effects of electroconvulsive therapy on hypothalamic-pituitary-thyroid axis activity in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1171-1175.
74. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res. 2003;12:3-21.
75. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1:189-195.
76. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11:1169-1180.
77. Biver F, Goldman S, Delvenne V, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry. 1994;36:381-388.
78. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628-3641.
79. Greicius MD, Flores BH, Menon V, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry. 2007;62:429-437.
80. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651-660.
81. Baxter LR Jr, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46:243-250.
82. Galynker II, Cai J, Ongseng F, et al. Hypofrontality and negative symptoms in major depressive disorder. J Nucl Med. 1998;39:608-612.
83. Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009;201:239-243.
84. Bolognini N, Pascual-Leone A, Fregni F. Using non-invasive brain stimulation to augment motor training-induced plasticity. J Neuroeng Rehabil. 2009;6:8.
85. Langguth B, Braun S, Aigner JM, et al. Repetitive transcranial magnetic stimulation in a patient suffering from depression and rheumatoid arthritis: evidence for immunomodulatory effects. Neuro Endocrinol Lett. 2005;26:314-316.
86. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-186.
87. Owen BM, Eccleston D, Ferrier IN, et al. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand. 2001;103:226-228.
88. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1044-1053.
89. Levine J, Barak Y, Chengappa KN, et al. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171-176.
90. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199-226.
91. Fregni F, Potvin K, Dasilva D, et al. Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain. Eur J Pain. 2011;15:53-60.
92. Okada K, Matsunaga K, Yuhi T, et al. The long-term high-frequency repetitive transcranial magnetic stimulation does not induce mRNA expression of inflammatory mediators in the rat central nervous system. Brain Res. 2002;957:37-41.
93. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res. 2009;43:947-961.
94. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev. 2009;33:699-771.
95. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10:1116-1124.
96. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88-109.
97. Li Y, Luikart BW, Birnbaum S, et al. Trkb regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron. 2008;59:399-412.
98. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251-3261.
99. Steingard RJ, Yurgelun-Todd DA, Hennen J, et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry. 2000;48:1053-1061.
100. Furtado CP, Hoy KE, Maller JJ, et al. Cognitive and volumetric predictors of response to repetitive transcranial magnetic stimulation (rTMS)Va prospective follow-up study [published online ahead of print May 17, 2012]. Psychiatry Res. 2012;202:12-19.
101. Micolaud-Franchi JA, Richieri R, Cermolacce M, et al. Parieto-temporal alpha EEG band power at baseline as a predictor of antidepressant treatment response with repetitive transcranial magnetic stimulation: a preliminary study [published online ahead of print January 12, 2012]. J Affect Disord. 2012;137:156-160.
102. Kito S, Hasegawa T, Koga Y. Cerebral blood flow in the ventromedial prefrontal cortex correlates with treatment response to low-frequency right prefrontal repetitive transcranial magnetic stimulation in the treatment of depression. Psychiatry Clin Neurosci. 2012;66:138-145.
103. Peng H, Zheng H, Li L, et al. High-frequency rTMS treatment increases white matter FA in the left middle frontal gyrus in young patients with treatment-resistant depression [published online ahead of print January 2, 2012]. J Affect Disord. 2012;136:249-257.
104. Croarkin PE, Wall CA, Nakonezny PA, et al. Increased cortical excitability with prefrontal high- frequency repetitive transcranial magnetic stimulation in adolescents with treatment-resistant major depressive disorder [published online ahead of print January 18, 2012]. J Child Adolesc Psychopharmacol. 2012;22:56-64.
105. Paillère Martinot ML, Martinot JL, Ringuenet D, et al. Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation [published online ahead of print August 17, 2011]. Neuropsychopharmacology. 2011;36:2710-2719.
106. Trojak B, Chauvet-Gelinier JC, Vergès B, et al. Significant increase in plasma thyroid-stimulating hormone during low-frequency repetitive transcranial magnetic stimulation. J Neuropsychiatry Clin Neurosci. 2011;23:E12.
107. Richieri R, Boyer L, Farisse J, et al. Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression [published online ahead of print June 7, 2011]. Eur J Nucl Med Mol Imaging. 2011;38:1715-1722.
108. Malaguti A, Rossini D, Lucca A, et al. Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation. Depress Anxiety. 2011;28:568-573.
109. Baeken C, De Raedt R, Bossuyt A, et al. The impact of HF-rTMS treatment on serotonin(2A) receptors in unipolar melancholic depression [published online ahead of print September 27, 2010]. Brain Stimul. 2011;4:104-111.
110. Kito S, Hasegawa T, Okayasu M, et al. A 6-month follow-up case report of regional cerebral blood flow changes in treatment-resistant depression after successful treatment with bilateral transcranial magnetic stimulation. J ECT. 2011;27:e12-e14.
111. Kozel FA, Johnson KA, Nahas Z, et al. Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. J ECT. 2011;27:5-10.
112. Khodayari-Rostamabad A, Reilly JP, Hasey GM, et al. Using pre-treatment electroencephalography data to predict response to transcranial magnetic stimulation therapy for major depression. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6418-6421.
113. Li CT, Wang SJ, Hirvonen J, et al. Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism [published online ahead of print July 3, 2010]. J Affect Disord. 2010;127:219-229.
114. Kuroda Y, Motohashi N, Ito H, et al. Chronic repetitive transcranial magnetic stimulation failed to change dopamine synthesis rate: preliminary L-[A-11C]DOPA positron emission tomography study in patients with depression. Psychiatry Clin Neurosci. 2010;64:659-662.
115. Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression [published online ahead of print June 23, 2010]. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1189-1195.
116. Baunce S, Izzetoglu M, Izzetoglu K, et al. Functional near-infrared spectroscopy. An emerging neuroimaging modality. IEEE Eng Med Biol Mag. 2006;25:54-62.
117. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Pascual-Leone A. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology. 2013;64:566-578.
118. Bermpohl F, Fregni F, Boggio PS, et al. Effect of low-frequency transcranial magnetic stimulation on an affective go/no-go task in patients with major depression: role of stimulation site and depression severity. Psychiatry Res. 2006;141:1-13.